Hepatic steatosis common. Biliary cirrhosis and portal hypertension (CF liver disease). Risk of gallstones. Drug‐induced liver injury (e.g., from antibiotics, CFTR modulators). This evidence concerns the gene CFTR and cystic fibrosis-related liver disease.